Indacaterol therapy in patients with COPD not receiving other maintenance treatment

Respiratory Medicine

Volumn 106, Issue 12, 2012, Pages 1706-1714

  Decramer, Marc ^a   Rossi, Andrea ^b   Lawrence, David ^c   McBryan, Danny ^d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

COPD; Indacaterol; Tiotropium

Indexed keywords

INDACATEROL; PLACEBO; TIOTROPIUM BROMIDE;

ADULT; ARTICLE; BACKACHE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; HYPERTENSION; INFLUENZA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT PARAMETERS; RHINOPHARYNGITIS; SINUSITIS; ST GEORGE RESPIRATORY QUESTIONNAIRE; TRANSITION DYSPNEA INDEX; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84867743840     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2012.08.022     Document Type: Article

References (29)

1. Global strategy for diagnosis, management and prevention of chronic obstructive pulmonary disease. Updated December 2011. At: http://www.goldcopd. org/ [accessed 17.01.12].
2. P.M. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, C. Jenkins, and P.W. Jones Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 356 2007 775 789
3. B.R. Celli, N.E. Thomas, J.A. Anderson, G.T. Ferguson, C.R. Jenkins, and P.W. Jones Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study Am J Respir Crit Care Med 178 2008 332 338
4. B. Celli, M. Decramer, S. Kesten, D. Liu, S. Mehra, and D.P. Tashkin Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 180 2009 948 955
5. M. Decramer, B. Celli, S. Kesten, T. Lystig, S. Mehra, and D.P. Tashkin Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial Lancet 374 2009 1171 1178
6. T. Troosters, B. Celli, T. Lystig, S. Kesten, S. Mehra, and D.P. Tashkin Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial Eur Respir J 36 2010 65 73
7. M. Decramer, and C.B. Cooper Treatment of COPD: the sooner the better? Thorax 65 2010 837 841
8. A.H. Morice, B. Celli, S. Kesten, T. Lystig, D. Tashkin, and M. Decramer COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT) Respir Med 104 2010 1659 1667
9. J. Vestbo, L.D. Edwards, P.D. Scanlon, J.C. Yates, A. Agusti, and P. Bakke Changes in forced expiratory volume in 1 second over time in COPD N Engl J Med 365 2011 1184 1192
10. C. Casanova, J.P. de Torres, A. Aguirre-Jaíme, V. Pinto-Plata, J.M. Marin, and E. Cordoba The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort Am J Respir Crit Care Med 184 2011 1015 1021
11. O. Kornmann, R. Dahl, S. Centanni, A. Dogra, R. Owen, and C. Lassen Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison Eur Respir J 37 2011 273 279
12. 2-agonist indacaterol versus twice-daily formoterol in COPD Thorax 65 2010 473 479
13. J.F. Donohue, C. Fogarty, J. Lötvall, D.A. Mahler, H. Worth, and A. Yorgancioglu Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium Am J Respir Crit Care Med 182 2010 155 162
14. M. Cazzola, W. MacNee, F.J. Martinez, K.F. Rabe, L.G. Franciosi, and P.J. Barnes Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur Respir J 31 2008 416 469
15. D.A. Mahler, and T.J. Witek Jr. The MCID of the transition dyspnea index is a total score of one unit COPD 2 2005 99 103
16. T.J. Witek Jr., and D.A. Mahler Meaningful effect size and patterns of response of the transition dyspnea index J Clin Epidemiol 56 2003 248 255
17. T.J. Witek Jr., and D.A. Mahler Minimal important difference of the transition dyspnoea index in a multinational clinical trial Eur Respir J 21 2003 267 272
18. P.W. Jones St. George's respiratory Questionnaire: MCID COPD 2 2005 75 79
19. P.W. Jones Issues concerning health-related quality of life in COPD Chest 107 Suppl. 5 1995 187S 193S
20. M. Ferrer, C. Villasante, J. Alonso, V. Sobradillo, R. Gabriel, and G. Vilagut Interpretation of quality of life scores from the St George's respiratory Questionnaire Eur Respir J 19 2002 405 413
21. S. Korn, O. Kornmann, L. Dunn, C. Lassen, D. Lawrence, and B. Kramer Efficacy of indacaterol is maintained in patients with moderate or less and severe or worse COPD Eur Respir J 38 Suppl. 55 2011 P860 [abstract]
22. P.W. Jones, D.A. Mahler, R. Gale, R. Owen, and B. Kramer Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD Respir Med 105 2011 892 899
23. P.W. Jones, N. Barnes, C. Vogelmeier, D. Lawrence, and B. Kramer Efficacy of indacaterol in the treatment of patients with COPD Prim Care Respir J 20 2011 380 388
24. P.W. Jones, and T.K. Bosh Quality of life changes in COPD patients treated with salmeterol Am J Respir Crit Care Med 155 1997 1283 1289
25. G. Boyd, A.H. Morice, J.C. Pounsford, M. Siebert, N. Peslis, and C. Crawford An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) Eur Respir J 10 1997 815 821
26. C. Fletcher, and R. Peto The natural history of chronic airflow obstruction Br Med J 1 6077 1977 1645 1648
27. G. Johansson, A. Lindberg, K. Romberg, L. Nordstrom, F. Gerken, and A. Roquet Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD Prim Care Respir J 17 2008 169 175
28. C.R. Jenkins, P.W. Jones, P.M. Calverley, B. Celli, J.A. Anderson, and G.T. Ferguson Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study Respir Res 10 2009 59
29. R. Buhl, L.J. Dunn, C. Disdier, C. Lassen, C. Amos, and M. Henley Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD Eur Respir J 38 2011 797 803